Netarsudil 0.02% Ophthalmic Solution Does Not Prevent Corticosteroid-Induced Ocular Hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension
Ophthalmology 2020 Oct 09;[EPub Ahead of Print], MO Price, MT Feng, FW PriceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.